MarkosWebWeb intelligence for the agentic economy

Nabla Bio

ActiveAI-native

We use AI to design antibodies for intractable diseases

nabla.bioAI readiness report

What it does

Our mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, we design antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. We are a well-funded, revenue-generating, bilingual company of wet- and dry-lab scientists, and are founded by AI and protein design experts from Harvard University.

Next to it in Healthcare and bio · AI-designed antibodies for drug discovery

  • CellChorusY Combinator S21

    The dynamic single-cell analysis company

  • Sequence BioY Combinator S19

    Discovering the true signals of disease to power life-changing drugs.

  • ResistanceBioY Combinator W19

    We solve drug resistance for cancer

  • FluoSpheraSOSV SOSV IndieBio NY 05

    Drug Discovery without animals

  • AMPLY DiscoveryTechstars TS 2023

    AMPLY Discovery — Turning the Dark Genome into Novel Medicines

  • Gordion BioscienceTechstars TS 2023

    Gordion Bioscience

  • InvitrisY Combinator W23

    Creating new protein-based drugs at scale

  • Ångström AIY Combinator S24

    Gen AI molecular simulations that reproduce wetlab results